Establishment of rhesus monkey model of autoimmunity type 1 diabetes
US9186421B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 26, 2010 |
| Grant date | Nov 17, 2015 |
| Priority date | — |
| Expiry date | Apr 29, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0362
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use of low dose streptozocin in the preparation of an animal model for screening drugs for treatment of antoimmune type 1 diabetes is disclosed, in which streptozocin is administrated intravenously at a dose of 15-30 mg/kg per time for 5 days and administrated again on the 7th day and 14th day after last time of offering drug. A method for preparing rhesus monkey model of autoimmune type 1 diabetes and autoimmune type 1 diabetes animal model obtained are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.